SPECIAL FEATURES

CCR Translations

4419 TP53 Mutations and Lung Cancer: Not All Mutations Are Created Equal
Ramaseswamy Govindan and Jason Weber
See related article, p. 4647

4422 "Companion Diagnostics": Has Their Time Come and Gone?
Fred R. Hirsch, Paul A. Bunn Jr, and Roy S. Herbst
See related article, p. 4488

CCR New Strategies

4425 New Strategies in Personalized Medicine for Solid Tumors: Molecular Markers and Clinical Trial Designs
Juliane M. Jurgensmeier, Joseph P. Eder, and Roy S. Herbst

CCR Perspectives in Drug Approval

4436 FDA Approval: Ado-Trastuzumab Emtansine for the Treatment of Patients with HER2-Positive Metastatic Breast Cancer

Molecular Pathways

4442 Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Felix Y. Feng, J. Chad Brenner, Maha Hussain, and Arul M. Chinnaiyan

CANCER THERAPY: CLINICAL

4449 Dose Selection, Pharmacokinetics, and Pharmacodynamics of BRAF Inhibitor Dabrafenib (GSK2118436)

4459 p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses
Nicola R. Hardwick, Mary Carroll, Teodora Kalcheva, Dajan Qian, Dean Lim, Lucille Leong, Peiguo Chu, Joseph Kim, Joseph Chao, Marwan Fakih, Yun Yen, Jonathan Espenschied, Joshua D. L. Ellenhorn, Don J. Diamond, and Vincent Chung

4471 Phase I Safety and Pharmacodynamic of Inecalcitol, a Novel VDR Agonist with Docetaxel in Metastatic Castration-Resistant Prostate Cancer Patients
Jacques Medioni, Gael Deplanque, Jean-Marc Ferrero, Tristan Maurina, Jean-Michel P. Rodier, Eric Raymond, Jorge Allyon, Gerard Maruani, Pascal Houllier, Sarah Mackenzie, Stephanie Renaux, Jean-Francois Dufour-Lamartine, Reza Elaidi, Celine Lerest, and Stephane Oudard

PERSONALIZED MEDICINE AND IMAGING

4478 Association of EGFR Expression Level and Cetuximab Activity in Patient-Derived Xenograft Models of Human Non–Small Cell Lung Cancer
Christiane Amendt, Eike Staub, Manja Friese-Hamim, Christoph Stroth, and Christoph Stroth

4488 Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit
See related commentary, p. 4422
### Table of Contents

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4499</td>
<td>A let-7 microRNA-Binding Site Polymorphism in KRAS Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy</td>
<td>Zenia Saridaki, Joanne B. Weidhaas, Heinz-Josef Lenz, Pierre Laurent-Puig, Bart Jacobs, Jef De Schutter, Wendy De Rooko, David W. Salzman, Wu Zhang, Dongyun Yang, Camilla Pilati, Olivier Bouché, Hubert Piessevaux, and Sabine Teijpar</td>
</tr>
<tr>
<td>4511</td>
<td>FcγRIla and FcγRIla Polymorphisms and Cetuximab Benefit in the Microscopic Disease Franchise</td>
<td>Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Wouterspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, and Ian Chau</td>
</tr>
<tr>
<td>4559</td>
<td>Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Laptatinib Unresponsiveness in HER2-Positive Gastric Cancer</td>
<td>Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchen Wang, Ruijao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jin Li</td>
</tr>
<tr>
<td>4574</td>
<td>SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38+ Hematologic Malignancies</td>
<td>Julia Deckert, Marie-Cécile Wetzel, Laura M. Bartle, Anna Skaletskaya, Victor S. Golkscher, François Vallée, Qing Zhou-Liu, Paul Ferrari, Stéphanie Pouzieux, Charlotte Lahoute, Charles Dumontet, Adriana Plesa, Marielle Chiron, Pascale Lejeune, Thomas Chittenden, Peter U. Park, and Véronique Blanc</td>
</tr>
<tr>
<td>4584</td>
<td>Reversible LSD1 Inhibition Interferes with Global EWS/ETS Transcriptional Activity and Impedes Ewing Sarcoma Tumor Growth</td>
<td>Savita Sankar, Emily R. Theisen, Jared Bears, Timothy Mulvihill, Laura M. Hoffman, Venkatattawmy Soma, Mary C. Beckerle, Sunil Sharma, and Stephen L. Lessnick</td>
</tr>
</tbody>
</table>

### CANCER THERAPY: PRECLINICAL

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4559</td>
<td>Functional Genetic Approach Identifies MET, HER3, IGF1R, INSR Pathways as Determinants of Laptatinib Unresponsiveness in HER2-Positive Gastric Cancer</td>
<td>Zhe Zhang, Jiping Wang, Dongmei Ji, Chenchen Wang, Ruijao Liu, Zheng Wu, Lian Liu, Dan Zhu, Jinjia Chang, Ruixuan Geng, Lei Xiong, Qiangyi Fang, and Jin Li</td>
</tr>
</tbody>
</table>

### BIOLOGY OF HUMAN TUMORS

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>4598</td>
<td>Large-Scale Characterization of DNA Methylation Changes in Human Gastric Carcinomas with and without Metastasis</td>
<td>Zhaojun Liu, Jun Zhang, Yanhong Gao, Ligong Pei, Jing Zhou, Liankun Gu, Lianhai Zhang, Budong Zhu, Naoko Hattori, Jiafu Ji, Yasuhito Yuasa, Wooho Kim, Toshikazu Ushijima, Huidong Shi, and Dajun Deng</td>
</tr>
</tbody>
</table>
Expression of Androgen and Estrogen Signaling Components and Stem Cell Markers to Predict Cancer Progression and Cancer-Specific Survival in Patients with Metastatic Prostate Cancer

Tetsuya Fujimura, Satoru Takahashi, Tomohiko Urano, Kenichi Takayama, Toru Sugihara, Daisuke Obinata, Yuta Yamada, Jimpei Kumaigai, Haruki Kume, Yasuyoshi Ouchi, Satoshi Inoue, and Yukio Homma

miR-409-3p/-5p Promotes Tumorigenesis, Epithelial-to-Mesenchymal Transition, and Bone Metastasis of Human Prostate Cancer


Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

Miguel A. Molina-Vila, Jordi Bertran-Alamillo, Amaya Gascó, Clara Mayo-de-las-Casas, María Sánchez-Ronco, Laia Pujantell-Pastor, Laura Bonanno, Adolfo G. Favaretto, Andrés F. Cardona, Alain Vergnenégre, Margarita Majem, Bartomeu Massuti, Teresa Morán, Enric Carcereny, Santiago Viteri, and Rafael Rosell

An Integrative Analysis of the Tumorigenic Role of TAZ in Human Non–Small Cell Lung Cancer


To “Grow” or “Go”: TMEM16A Expression as a Switch between Tumor Growth and Metastasis in SCCHN

Daniel J. Shiwasaki, Chunbo Shao, Anke Bill, Jean Kim, Dong Xiao, Carol A. Bertrand, Raja S. Seethala, Daisuke Sano, Jeffery N. Myers, Patrick Ha, Jennifer Grandis, L. Alex Gaither, Manojkumar A. Puthenveedu, and Umamaheswar Duvvuri

TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome

Tiantian Sun, Wan Du, Hua Xiong, Yanan Yu, Yurong Weng, Linlin Ren, Huijun Zhao, Yingchao Wang, Yingxuan Chen, Jie Xu, Yongbing Xiang, Wenxin Qin, Weibiao Cao, Weiping Zou, Haoyan Chen, Jie Hong, and Jing-Yuan Fang

Decreased Expression of miR216a Contributes to Non–Small-Cell Lung Cancer Progression

Ren-Tao Wang, Meng Xu, Cheng-Xiong Xu, Zhi-Gang Song, and Hua Jin

GSK-3β–Regulated N-Acetyltransferase 10 Is Involved in Colorectal Cancer Invasion

Hong Zhang, Wei Hou, Hua-Li Wang, Hai-Jing Liu, Xin-Ying Jia, Xing-Zheng Zheng, Yong-Xin Zou, Xin Li, Lin Hou, Michael A. McNutt, and Bo Zhang
ABOUT THE COVER

The cover shows the crystal structure of the SAR650984-Fab in complex with human CD38 resolved at 1.53 Å resolution. A close-up view of the epitope highlights the interface between human CD38 and SAR650984-Fab, which involves mainly antibody heavy chain CDR loop H3 (yellow) and light chain CDR loops L1, L2 and L3 (green). For details, see the article by Deckert and colleagues on page 4574 of this issue.